AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36335079
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy receipt
Trial: 36335079
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy use
Trial: 36335217
Drug: gedatolisib (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gedatolisib (180 mg QW) plus cisplatin
Trial: 36335217
Drug: gedatolisib (90-310
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gedatolisib (90-310 mg QW) plus docetaxel
Trial: 36335479
Drug: Intravenous acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acetazolamide (500 mg once daily)
Trial: 36335915
Drug: Apixaban (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (2.5 mg BID)
Trial: 36335915
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonist (VKA) phenprocoumon (INR 2.0 to 3.0)
Trial: 36336684
Drug: Insulin sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin sensitivity measures (HOMA2S, Matsuda ISI, MinMod SI)
Trial: 36336899
Drug: Tumor treating
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor treating fields (TTFields) with concurrent chemoradiation
Trial: 36337437
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (CoQ10) 500 mg/day for 6 weeks
Trial: 36337437
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (CoQ10) 500 mg/day
Trial: 36337613
Drug: Resistant starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant starch type 4 (RS4) intake of 12 g/day for 12 weeks
Trial: 36337904
Drug: Long drug-eluting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long drug-eluting stents (DES)
Trial: 36337904
Drug: Spot drug-eluting
RxNorm normalized name: Cold Spot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spot drug-eluting stents (DES)
Trial: 36338362
Drug: Second-generation drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation drug-eluting stent (DES)
Trial: 36338362
Drug: First-generation drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-generation drug-eluting stent (DES)
Trial: 36338415
Drug: Persistent high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Persistent high RIR (hsCRP ≥2 mg/L)
Trial: 36338481
Drug: 7% solution
RxNorm normalized name: Aminosyn 7% Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7% solution of xylitol
Trial: 36338481
Drug: 7% solution
RxNorm normalized name: Aminosyn 7% Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7% solution of free sugars (glucose, fructose, sucrose)
Trial: 36338546
Drug: DDK inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDK inhibitor
Trial: 36338546
Drug: WEE1 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: WEE1 inhibitor
Trial: 36338743
Drug: Third dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third dose (booster) of COVID-19 mRNA vaccination (Pfizer-BioNTech or Moderna)
Trial: 36338743
Drug: First two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First two doses of COVID-19 mRNA vaccination
Trial: 36339126
Drug: Ticagrelor plus
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor plus aspirin (T+A)
Trial: 36339533
Drug: Compound methyl
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound methyl salicylate liniment (Ammeltz)
Trial: 36339707
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of spa rehabilitation with ubiquinol therapy
Trial: 36339926
Drug: Savolitinib, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Savolitinib, a selective MET inhibitor
Trial: 36342102
Drug: FS118 (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FS118 (800 μg to 0.3 mg/kg followed by 1 to 20 mg/kg weekly)
Trial: 36342102
Drug: FS118 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FS118 (1 mg/kg or greater)
Trial: 36342104
Drug: Pfizer/BioNTech BNT162b2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfizer/BioNTech BNT162b2 or Oxford/AstraZeneca ChAdOx1 vaccine; 99 patients received at least one dose of vaccine prior to, or during the study.
Trial: 36342116
Drug: Methylprednisolone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (30 mg/kg body weight)
Trial: 36342173
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy in cohort 1
Trial: 36342173
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy in cohort 2
Trial: 36342342
Drug: Adjuvant abemaciclib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant abemaciclib combined with endocrine therapy (ET)
Trial: 36342853
Drug: Investigational extended-wear
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational extended-wear insulin infusion set (IIS)
Trial: 36342853
Drug: Conventional Teflon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Teflon angled insulin infusion set (IIS)
Trial: 36342912
Drug: Praziquantel (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (two doses)
Trial: 36342972
Drug: Antidiabetic medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidiabetic medications (ADMs) including biguanides (metformin), sulfonylureas (gliclazide, glibenclamide, glimepiride, glipizide, glyclopyramide), insulin (premix, basal, basal/bolus), DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, linagliptin)
Trial: 36343674
Drug: Cutoff values
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cutoff values for rectal submucosa in CD
Trial: 36343674
Drug: Cutoff values
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cutoff values for rectal mucosa in UC
Trial: 36344555
Drug: Nuclear Transport
RxNorm normalized name: oxymetazoline hydrochloride Ophthalmic Solution [Ocuclear]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nuclear Transport Checkpoint Inhibitor (NTCI) topical treatment
Trial: 36344663
Drug: Moderate correlations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate correlations (P < 0.001) of the 24 h urinary Na/K ratio with 24 h urinary Na and K excretion
Trial: 36344711
Drug: Nanoliposomal irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanoliposomal irinotecan (nal-IRI) at 70 mg/m² during HIPEC
Trial: 36346005
Drug: Educational interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational interventions (face-to-face or e-learning focusing on infective area, basic gestures, COVID clinical management and intensive care medicine)
Trial: 36346044
Drug: Docetaxel and
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel and fluorouracil (infusional fluorouracil of 200 mg/m2)
Trial: 36346118
Drug: FIT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIT with a positivity threshold of >15 mcg haemoglobin/g faeces, interval between rounds varied between 1.5 and 3.5 years
Trial: 36346229
Drug: Islatravir 60
RxNorm normalized name: Islatravir
DrugBank: Islatravir (DB15653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islatravir 60 mg administered orally
Trial: 36346366
Drug: ERK-MAPK inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERK-MAPK inhibitor (ulixertinib) in combination with CDK4/6 inhibitor (palbociclib)
Trial: 36346366
Drug: Novel therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel therapeutic combinations validated using siRNA and small-molecule inhibitors
Trial: 36346679
Drug: Integrative medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative medicine (IM) intervention, single 30-minute session combining acupuncture, mind-body, and/or manual-movement modalities.
Trial: 36347128
Drug: Endovascular techniques
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular techniques for treatment of ALI
Trial: 36350312
Drug: Molibresib 75
RxNorm normalized name: Molibresib
DrugBank: Molibresib (DB16239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molibresib 75 mg daily for MDS
Trial: 36350312
Drug: Molibresib 60
RxNorm normalized name: Molibresib
DrugBank: Molibresib (DB16239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molibresib 60 mg daily for CTCL
Trial: 36350359
Drug: Total vitamin
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total vitamin D intake from food and supplements
Trial: 36350362
Drug: Cardiac Resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac Resynchronization Therapy Device
Trial: 36350598
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for Alcohol Use Disorder
Trial: 36350899
Drug: cabazitaxel chemotherapy
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cabazitaxel chemotherapy
Trial: 36351064
Drug: Welch Allyn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Welch Allyn Connex® Spot Monitor/Hillrom Connecta™ automated solution
Trial: 38269049
Drug: COVID-19 convalescent
RxNorm normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 convalescent plasma (CCP) therapy
Trial: 36351728
Drug: Remifentanil dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil dose titration
Trial: 36351741
Drug: Erector spinae
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erector spinae plane block (ESPB) with 30 mL 2.5 mg/mL ropivacaine and 0.3 mL gadolinium.
Trial: 36351814
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis (IVT) and/or endovascular treatment (EVT)
Trial: 36351931
Drug: CoVLP+AS03 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoVLP+AS03 vaccine (3.75 µg CoVLP/dose + AS03), administered as two intramuscular doses, 21 days apart.
Trial: 36352028
Drug: AZD8931 (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8931 (160 mg bd) with FOLFIRI
Trial: 36352054
Drug: Aprocitentan 25
RxNorm normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprocitentan 25 mg single oral dose
Trial: 36352103
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL t.i.d. treatment with a full-spectrum, high-CBD sublingual solution (9.97 mg/mL CBD, 0.23 mg/mL Δ-9-tetrahydrocannabinol)
Trial: 36353661
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment sequences including ABI-DOCE, ABI-ENZA, ABI-RAD, DOCE-ABI, DOCE-CABA, DOCE-ENZA, ENZA-DOCE
Trial: 36355054
Drug: AZD8205 (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8205 (3.5 mg/kg single administration)
Trial: 36355054
Drug: AZD5305 (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5305 (in combination with AZD8205)
Trial: 36355259
Drug: Concurrent chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiation with Tumor Treating Fields (TTFields, 200 kHz), standard concurrent temozolomide (TMZ), and scalp-sparing radiation (60 Gy in 30 fractions). Maintenance therapy included standard TMZ and continuation of TTFields.
Trial: 36355775
Drug: M72/AS01 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M72/AS01 vaccine (two immunizations)
Trial: 38296630
Drug: Acetazolamide (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (375 mg/day)
Trial: 36356418
Drug: Internal mammary
RxNorm normalized name: Bovine internal mammary artery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal mammary chain radiation therapy (RT)
Trial: 36356418
Drug: Normofractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normofractionated radiation therapy (RT)
Trial: 36356599
Drug: Non-viral precision
RxNorm normalized name: covid-19, viral vector, non-replicating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-viral precision T cell receptor replacement
Trial: 36356972
Drug: Methylprednisolone 80
RxNorm normalized name: methylPREDNISolone 80 mg/mL injectable suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 80 mg as a continuous daily infusion for 8 days followed by slow tapering
Trial: 36356972
Drug: Conventional dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conventional dexamethasone (6 mg daily for 7-10 days)
Trial: 37270762
Drug: Ciltacabtagene autoleucel
RxNorm normalized name: ciltacabtagene autoleucel
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciltacabtagene autoleucel (cilta-cel) therapy
Trial: 36357392
Drug: Branaplam (splicing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branaplam (splicing modulator)
Trial: 36357415
Drug: Neoadjuvant camrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neoadjuvant camrelizumab plus concurrent chemoradiotherapy
Trial: 36357877
Drug: PrEP awareness
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PrEP awareness influenced by external factors such as social media and community knowledge about HIV treatment and prevention.
Trial: 36357877
Drug: Joining the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Joining the HIV vaccine trial preparedness study.
Trial: 36358702
Drug: Calcium electroporation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium electroporation (CaEP) with intratumoral injection of calcium gluconate followed by reversible electroporation.
Trial: 36358702
Drug: Calcium electroporation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium electroporation (CaEP) treatment.
Trial: 36360766
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy sleep programme sessions (2 sessions)
Trial: 36367717
Drug: COVID-19 vaccine
RxNorm normalized name: COVID-19 VACCINE
DrugBank: VidPrevtyn Beta (DB16427)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 vaccine uptake
Trial: 36369507
Drug: Telehealth support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth support comprising automated twice-weekly telephone calls with a specialist nurse triaging alerts.
Trial: 36369848
Drug: EDP-297 20-600
RxNorm normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP-297 20-600 μg single doses
Trial: 36369848
Drug: EDP-297 5-90
RxNorm normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP-297 5-90 μg once daily for 14 days
Trial: 36369848
Drug: EDP-297 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP-297 (all doses)
Trial: 36369848
Drug: EDP-297 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP-297 (60 μg MAD)
Trial: 36370233
Drug: Fixed-combination bimatoprost
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fixed-combination bimatoprost 0.03%/timolol 0.5% ophthalmic solution (FCBT; Ganfort), one drop per eye every evening
Trial: 36370233
Drug: Fixed-combination bimatoprost
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fixed-combination bimatoprost 0.03%/timolol 0.5% ophthalmic solution (FCBT; Ganfort)
Trial: 36370742
Drug: Olutasidenib monotherapy
RxNorm normalized name: Olutasidenib
DrugBank: Olutasidenib (DB16267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olutasidenib monotherapy (150 mg once daily, 150 mg twice per day, 300 mg once daily)
Trial: 36370742
Drug: Olutasidenib in
RxNorm normalized name: Olutasidenib
DrugBank: Olutasidenib (DB16267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olutasidenib in combination with azacitidine (75 mg/m2)
Trial: 36371226
Drug: Compartmental radioimmunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compartmental radioimmunotherapy (cRIT) with anti-B7H3 murine monoclonal antibody omburtamab injected intraventricularly, 100 radioiodinated omburtamab injections at a recommended phase 2 dose of 1850 MBq/injection.
Trial: 36371226
Drug: Compartmental radioimmunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compartmental radioimmunotherapy (cRIT) with anti-B7H3 murine monoclonal antibody omburtamab injected intraventricularly.
Trial: 36371408
Drug: 3.75 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 µg CoVLP+AS03
Trial: 36372245
Drug: AT-001 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT-001 (1000 mg BID)
Trial: 36372245
Drug: AT-001 (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT-001 (1500 mg BID)
Trial: 36372356
Drug: MSC infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MSC infusion on the day of leukocyte recovery to 1000 cells/μL (engraftment, day E0)
Trial: 36372356
Drug: MSC infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MSC infusion on day E0
Trial: 36372442
Drug: Fostemsavir co-administration
RxNorm normalized name: fostemsavir
DrugBank: Fostemsavir (DB11796)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostemsavir co-administration with hormone therapy
Trial: 36372442
Drug: Fostemsavir with
RxNorm normalized name: fostemsavir
DrugBank: Fostemsavir (DB11796)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostemsavir with combined oral contraceptives (COCs)
Trial: 36372442
Drug: Other oestrogen-based
RxNorm normalized name: Other estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other oestrogen-based therapies with fostemsavir
Trial: 36372873
Drug: ≥ 50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ≥ 50% reductions in CSF ctDNA concentrations after 8 weeks of treatment
Trial: 36373234
Drug: Sex-hormone-binding globulin
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sex-hormone-binding globulin in PCOS patients
Trial: 36373249
Drug: Partially HLA-matched,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partially HLA-matched, third-party, cryopreserved SARS-CoV-2-specific T cells (ALVR109) in combination with other antiviral agents
Trial: 36375653
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of N20Amp decrease and N20Amp < 1.23 µV at 72 h
Trial: 36375971
Drug: Outpatient parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient parenteral antimicrobial therapy (OPAT)
Trial: 36375981
Drug: FLOT chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin plus docetaxel)
Trial: 36375981
Drug: ECF/ECX chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECF/ECX chemotherapy (epirubicin, cisplatin plus fluorouracil or capecitabine)
Trial: 36376393
Drug: ChulaCov19 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChulaCov19 vaccine at 10 μg
Trial: 36376393
Drug: ChulaCov19 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChulaCov19 vaccine at 25 μg
Trial: 36376393
Drug: ChulaCov19 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChulaCov19 vaccine at 50 μg
Trial: 36376636
Drug: Combination rationale
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination rationale (n=1786)
Trial: 37348519
Drug: mRNA-1273 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 (50 μg)
Trial: 36376733
Drug: mRNA-1273 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 (50 μg and 100 μg)